ITIF：2024年生物制药政策的证据：呼吁研究公共政策对药物开发投资的影响报告（英文版）

The scope and magnitude of the trade-off between immediate savings from lower drug prices and future health benefits from clinical development remain poorly understood and quantified. To support rigorous evaluations and inform evidence-based policymaking, it is crucial to invest in this area through research grants and improved access to federal and private data.